[
  {
    "ts": "2025-11-05T05:00:00+00:00",
    "headline": "AP Top Financial News at 12:29 a.m. EST",
    "summary": "Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer",
    "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "92dfe834-3e17-3aaa-8c05-26f0aa02982f",
      "content": {
        "id": "92dfe834-3e17-3aaa-8c05-26f0aa02982f",
        "contentType": "STORY",
        "title": "AP Top Financial News at 12:29 a.m. EST",
        "description": "",
        "summary": "Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer",
        "pubDate": "2025-11-05T05:00:00Z",
        "displayTime": "2025-11-05T05:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T05:00:00+00:00",
    "headline": "AP Top Extended Financial Headlines at 12:29 a.m. EST",
    "summary": "Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera",
    "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "b2634554-8ded-3efe-a40e-4b24b3ebe503",
      "content": {
        "id": "b2634554-8ded-3efe-a40e-4b24b3ebe503",
        "contentType": "STORY",
        "title": "AP Top Extended Financial Headlines at 12:29 a.m. EST",
        "description": "",
        "summary": "Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera",
        "pubDate": "2025-11-05T05:00:00Z",
        "displayTime": "2025-11-05T05:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T04:31:04+00:00",
    "headline": "Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts",
    "summary": "A new regulatory filing shows that billionaire investor Michael Burry's hedge fund Scion Asset Management purchased five million put options on Palantir Technologies, Inc. (NASDAQ:PLTR) and one million put options on NVIDIA Corp. (NASDAQ:NVDA), among ...",
    "url": "https://finance.yahoo.com/news/michael-burry-super-bearish-palantir-043104113.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "0c1283d4-df14-3ee2-9d0a-6d5623cb5e0c",
      "content": {
        "id": "0c1283d4-df14-3ee2-9d0a-6d5623cb5e0c",
        "contentType": "STORY",
        "title": "Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts",
        "description": "",
        "summary": "A new regulatory filing shows that billionaire investor Michael Burry's hedge fund Scion Asset Management purchased five million put options on Palantir Technologies, Inc. (NASDAQ:PLTR) and one million put options on NVIDIA Corp. (NASDAQ:NVDA), among ...",
        "pubDate": "2025-11-05T04:31:04Z",
        "displayTime": "2025-11-05T04:31:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/benzinga_79/fddb4c00d29ba7af97f6f5e3297816ce",
          "originalWidth": 720,
          "originalHeight": 480,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TTciiphdQR88uNeAEBOPyA--~B/aD00ODA7dz03MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/benzinga_79/fddb4c00d29ba7af97f6f5e3297816ce.cf.webp",
              "width": 720,
              "height": 480,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pQuyOpoLC5jVJ3Eq2VY_ZA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/benzinga_79/fddb4c00d29ba7af97f6f5e3297816ce.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "https://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/michael-burry-super-bearish-palantir-043104113.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/michael-burry-super-bearish-palantir-043104113.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "GOOGL"
            },
            {
              "symbol": "LULU"
            },
            {
              "symbol": "SLM"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "EL"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "MELI"
            },
            {
              "symbol": "UNH"
            },
            {
              "symbol": "GC=F"
            },
            {
              "symbol": "HAL"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "ORCL"
            },
            {
              "symbol": "MOH"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "IDLE-USD"
            },
            {
              "symbol": "OPAI.PVT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T00:37:20+00:00",
    "headline": "Pfizer (PFE) Profit Margins Double—Challenges Bearish View Despite $4.7B Loss and Revenue Headwinds",
    "summary": "Pfizer (PFE) posted notable earnings growth, with net profit margins improving to 15.6%, a lift from the previous period’s 7%. Year-over-year, EPS growth soared 133.3%, marking a sharp reversal from the company’s five-year average decline of 13.2% per year, even as a significant one-off loss of $4.7 billion weighed on the latest results. Looking ahead, investors are weighing the company’s stronger margins and attractive valuation multiples against forecasts for a 3.2% annual decline in...",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-profit-margins-double-003720893.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "236bf18b-c086-3c32-82b7-502c6d20133d",
      "content": {
        "id": "236bf18b-c086-3c32-82b7-502c6d20133d",
        "contentType": "STORY",
        "title": "Pfizer (PFE) Profit Margins Double—Challenges Bearish View Despite $4.7B Loss and Revenue Headwinds",
        "description": "",
        "summary": "Pfizer (PFE) posted notable earnings growth, with net profit margins improving to 15.6%, a lift from the previous period’s 7%. Year-over-year, EPS growth soared 133.3%, marking a sharp reversal from the company’s five-year average decline of 13.2% per year, even as a significant one-off loss of $4.7 billion weighed on the latest results. Looking ahead, investors are weighing the company’s stronger margins and attractive valuation multiples against forecasts for a 3.2% annual decline in...",
        "pubDate": "2025-11-05T00:37:20Z",
        "displayTime": "2025-11-05T00:37:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-profit-margins-double-003720893.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-profit-margins-double-003720893.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T05:32:25+00:00",
    "headline": "PFE Q3 Deep Dive: Pipeline, Cost Controls, and Business Development Shape Outlook",
    "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.87 per share was 37% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/pfe-q3-deep-dive-pipeline-053225703.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "2d150d0b-ad11-37ce-b0c3-dc67664e8eec",
      "content": {
        "id": "2d150d0b-ad11-37ce-b0c3-dc67664e8eec",
        "contentType": "STORY",
        "title": "PFE Q3 Deep Dive: Pipeline, Cost Controls, and Business Development Shape Outlook",
        "description": "",
        "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.87 per share was 37% above analysts’ consensus estimates.",
        "pubDate": "2025-11-05T05:32:25Z",
        "displayTime": "2025-11-05T05:32:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "PFE Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o3tZoPUio75qXATbHoc_Hg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5rZqD7vIoFGnsFYAS_Ztw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfe-q3-deep-dive-pipeline-053225703.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfe-q3-deep-dive-pipeline-053225703.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T05:00:00+00:00",
    "headline": "AP Top Financial News at 3:49 a.m. EST",
    "summary": "Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer",
    "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "92dfe834-3e17-3aaa-8c05-26f0aa02982f",
      "content": {
        "id": "92dfe834-3e17-3aaa-8c05-26f0aa02982f",
        "contentType": "STORY",
        "title": "AP Top Financial News at 3:49 a.m. EST",
        "description": "",
        "summary": "Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer",
        "pubDate": "2025-11-05T05:00:00Z",
        "displayTime": "2025-11-05T05:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T05:00:00+00:00",
    "headline": "AP Top Extended Financial Headlines at 3:49 a.m. EST",
    "summary": "Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera",
    "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "b2634554-8ded-3efe-a40e-4b24b3ebe503",
      "content": {
        "id": "b2634554-8ded-3efe-a40e-4b24b3ebe503",
        "contentType": "STORY",
        "title": "AP Top Extended Financial Headlines at 3:49 a.m. EST",
        "description": "",
        "summary": "Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera",
        "pubDate": "2025-11-05T05:00:00Z",
        "displayTime": "2025-11-05T05:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T07:22:31+00:00",
    "headline": "Google Clears DOJ Antitrust Hurdle for $32 Billion Wiz Deal",
    "summary": "After the companies first announced their tie-up in March, the Justice Department opened up an in-depth probe of the deal, Bloomberg reported in June.  Wiz Chief Executive Officer Assaf Rappaport confirmed at a Wall Street Journal event on Tuesday that the DOJ concluded its review, but the deal is still under scrutiny by other antitrust regulators.  A Google spokesperson didn’t immediately respond outside regular business hours to a request for comment.",
    "url": "https://finance.yahoo.com/news/google-clears-doj-antitrust-hurdle-072231203.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "2ffa5cb0-f75e-30eb-a755-3afe3c1a2942",
      "content": {
        "id": "2ffa5cb0-f75e-30eb-a755-3afe3c1a2942",
        "contentType": "STORY",
        "title": "Google Clears DOJ Antitrust Hurdle for $32 Billion Wiz Deal",
        "description": "",
        "summary": "After the companies first announced their tie-up in March, the Justice Department opened up an in-depth probe of the deal, Bloomberg reported in June.  Wiz Chief Executive Officer Assaf Rappaport confirmed at a Wall Street Journal event on Tuesday that the DOJ concluded its review, but the deal is still under scrutiny by other antitrust regulators.  A Google spokesperson didn’t immediately respond outside regular business hours to a request for comment.",
        "pubDate": "2025-11-05T07:22:31Z",
        "displayTime": "2025-11-05T07:22:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/5a62293414e24b8304daf34d23631219",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4Nhvb_4r8kzx9IxUmdMHcw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/5a62293414e24b8304daf34d23631219.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/O3wDoCSB_ybxr60tJOVCWg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/5a62293414e24b8304daf34d23631219.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/google-clears-doj-antitrust-hurdle-072231203.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/google-clears-doj-antitrust-hurdle-072231203.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GOOGL"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T05:00:00+00:00",
    "headline": "AP Top Financial News at 4:22 a.m. EST",
    "summary": "Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer",
    "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "92dfe834-3e17-3aaa-8c05-26f0aa02982f",
      "content": {
        "id": "92dfe834-3e17-3aaa-8c05-26f0aa02982f",
        "contentType": "STORY",
        "title": "AP Top Financial News at 4:22 a.m. EST",
        "description": "",
        "summary": "Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer",
        "pubDate": "2025-11-05T05:00:00Z",
        "displayTime": "2025-11-05T05:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T05:00:00+00:00",
    "headline": "AP Top Extended Financial Headlines at 4:22 a.m. EST",
    "summary": "Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera",
    "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "b2634554-8ded-3efe-a40e-4b24b3ebe503",
      "content": {
        "id": "b2634554-8ded-3efe-a40e-4b24b3ebe503",
        "contentType": "STORY",
        "title": "AP Top Extended Financial Headlines at 4:22 a.m. EST",
        "description": "",
        "summary": "Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera",
        "pubDate": "2025-11-05T05:00:00Z",
        "displayTime": "2025-11-05T05:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T10:15:00+00:00",
    "headline": "Here's Why Shares in Viking Therapeutics Shot Higher in October",
    "summary": "Three factors took Viking's shares higher in the month.",
    "url": "https://www.fool.com/investing/2025/11/05/heres-why-shares-in-viking-therapeutics-shot-highe/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "442465d0-d392-3e10-a36f-a08209cc7cc1",
      "content": {
        "id": "442465d0-d392-3e10-a36f-a08209cc7cc1",
        "contentType": "STORY",
        "title": "Here's Why Shares in Viking Therapeutics Shot Higher in October",
        "description": "",
        "summary": "Three factors took Viking's shares higher in the month.",
        "pubDate": "2025-11-05T10:15:00Z",
        "displayTime": "2025-11-05T10:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/89d7588798113f0fa43e6a4a04a23dbd",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A phone with Viking Therapeutics logo displayed on it.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wg8G7OI1eN8IuZ9mRf0sYg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/89d7588798113f0fa43e6a4a04a23dbd.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5KFo5nXB9HZLFelSAyLuOQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/89d7588798113f0fa43e6a4a04a23dbd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/05/heres-why-shares-in-viking-therapeutics-shot-highe/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-shares-viking-therapeutics-101500376.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T10:06:00+00:00",
    "headline": "Nucleic Acid Therapeutics Market Report 2025: Competition Intensifies as Pfizer, Sanofi, Novartis, Moderna, BioNTech Expand Antisense and RNA Platform Innovations - Long-term Forecast to 2029 & 2034",
    "summary": "The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, and increased RNA therapeutics adoption. Key opportunities include precision medicine demand, mRNA applications, advanced delivery platforms, AI integration, and regulatory support. Nucleic Acid Therapeutics Market Nucleic Acid Therapeutics Market Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The \"Nucleic Acid Therapeutics Market Report 2025\" has been added to ResearchAndMark",
    "url": "https://finance.yahoo.com/news/nucleic-acid-therapeutics-market-report-100600971.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "fb9b3764-0558-360c-b239-070b4667145e",
      "content": {
        "id": "fb9b3764-0558-360c-b239-070b4667145e",
        "contentType": "STORY",
        "title": "Nucleic Acid Therapeutics Market Report 2025: Competition Intensifies as Pfizer, Sanofi, Novartis, Moderna, BioNTech Expand Antisense and RNA Platform Innovations - Long-term Forecast to 2029 & 2034",
        "description": "",
        "summary": "The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, and increased RNA therapeutics adoption. Key opportunities include precision medicine demand, mRNA applications, advanced delivery platforms, AI integration, and regulatory support. Nucleic Acid Therapeutics Market Nucleic Acid Therapeutics Market Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The \"Nucleic Acid Therapeutics Market Report 2025\" has been added to ResearchAndMark",
        "pubDate": "2025-11-05T10:06:00Z",
        "displayTime": "2025-11-05T10:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d76177194e15f4fca5ad163bbf1a5a2b",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Nucleic Acid Therapeutics Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y_uzMvN4jpuzj0ey1IvG_A--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d76177194e15f4fca5ad163bbf1a5a2b.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rmC1iOZCaHctoRedXCRySg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d76177194e15f4fca5ad163bbf1a5a2b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nucleic-acid-therapeutics-market-report-100600971.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nucleic-acid-therapeutics-market-report-100600971.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "BNTX"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "NOVN.SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T10:00:00+00:00",
    "headline": "Novo Nordisk Stock Up After Earnings. Guidance Cut on These Weight-Loss Drug Fears.",
    "summary": "The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.",
    "url": "https://www.barrons.com/articles/novo-nordisk-earnings-stock-price-997bc7ca?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ba684ec8-e1fe-37a7-b161-5472c35e891e",
      "content": {
        "id": "ba684ec8-e1fe-37a7-b161-5472c35e891e",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Up After Earnings. Guidance Cut on These Weight-Loss Drug Fears.",
        "description": "",
        "summary": "The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.",
        "pubDate": "2025-11-05T10:00:00Z",
        "displayTime": "2025-11-05T10:00:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ba684ec8-e1fe-37a7-b161-5472c35e891e/novo-nordisk-stock-up-after.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/33cdf10977edf16fd4f87e8324176083",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xyHlGWIyozQ11qgbu0Gisw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/33cdf10977edf16fd4f87e8324176083.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N2uBceIjOWjhcBVcyJWYqA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/33cdf10977edf16fd4f87e8324176083.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-earnings-stock-price-997bc7ca?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T05:00:00+00:00",
    "headline": "AP Top Financial News at 5:43 a.m. EST",
    "summary": "Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer",
    "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "92dfe834-3e17-3aaa-8c05-26f0aa02982f",
      "content": {
        "id": "92dfe834-3e17-3aaa-8c05-26f0aa02982f",
        "contentType": "STORY",
        "title": "AP Top Financial News at 5:43 a.m. EST",
        "description": "",
        "summary": "Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer",
        "pubDate": "2025-11-05T05:00:00Z",
        "displayTime": "2025-11-05T05:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-financial-news-12-050000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T05:00:00+00:00",
    "headline": "AP Top Extended Financial Headlines at 5:43 a.m. EST",
    "summary": "Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera",
    "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "b2634554-8ded-3efe-a40e-4b24b3ebe503",
      "content": {
        "id": "b2634554-8ded-3efe-a40e-4b24b3ebe503",
        "contentType": "STORY",
        "title": "AP Top Extended Financial Headlines at 5:43 a.m. EST",
        "description": "",
        "summary": "Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera",
        "pubDate": "2025-11-05T05:00:00Z",
        "displayTime": "2025-11-05T05:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ap-top-extended-financial-headlines-050000775.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]